Despite advances in diagnosis and treatment, it is difficult to accurately predict the evolution of a given tumor, and therefore to evaluate the response of each patient to their treatment.

Hence, under similar conditions and treatment levels, the life expectancy of two patients affected by apparently the same cancer may differ by several months or even years.

The clinical and biological heterogeneity of cancers, reflecting their complex and combinatory molecular nature, are largely responsible for therapeutic failures.

Characterizing the genetic mechanisms initiating these diseases, scientists have defined new molecular classes of cancer, organized under the same diagnosis and the same treatment, thereby enlightening oncologists and their patients’ decision.

Pioneer in this rapidly expanding field, Ipsogen markets more than 60 tests already used routinely in over 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia. The Company is now also focusing on breast cancer; its initial goal will be to provide diagnostic information that remained unavailable until now.

Aiming for the world’s top spot in the molecular profiling of cancer, Ipsogen's diagnostic tools will make a difference for patients, the medical profession and society in general in all 5 continents.